Instytut Diabetologii Sp. z o.o.

Warsaw 13 trials 4 recruiting

13 Registered trials

4 Currently recruiting

Organisation

Instytut Diabetologii Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100043166

Address

Ul. Raclawicka 129/2u, 02-117, Poland

Departments

Instytut Diabetologii Sp. z o.o.
Instytut Diabetologii, Poradnia Diabetologiczna, Poradnia Diabetologiczna dla Dzieci
Instytut Diabetologii, ul. Raclawicka 129 lok. 2U
N/A
N/D
NA
Poradnia Diabetologiczna, Poradnia Diabetologiczna dla Dzieci

Clinical trials at this site (13)

Search interface

EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
SAFEGUARD (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes) Study Recruiting

2025-521560-36-00 Type 1 Diabetes 4 2026-04-22
A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab… Recruiting

2024-519494-19-00 Nutritional and metabolic diseases 5 2025-12-22
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Type 1 diabetes mellitus 4 2024-02-02
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Ended

2025-523974-18-00 Obesity 5 2026-04-30
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) A Study of Orforglipron (LY3502970) in Adolescent Partici… Ended

2024-514081-40-00 Obesity, Overweight 5 2025-06-06
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab Ended

2024-516543-26-00 Type 1 Diabetes Mellitus 5 2021-07-23
A Phase 2 study (NEPTUNE-17) to evaluate efficacy and safety of GSK3858279 in DPNP. Ended

2022-502313-28-00 Diabetic Peripheral Neuropathic Pain 4 2023-12-14
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended

2022-502678-18-00 Type 2 diabetes 5 2023-11-07
A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended

2023-506931-13-00 Overweight and obesity and type 2 diabetes 5 2023-01-30
A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended

2024-513304-33-00 Type 1 diabetes mellitus 5 2022-03-17
Ertugliflozin Pediatric Study Ended

2022-501085-21-00 Type 2 Diabetes Mellitus 5 2019-11-29